KR20260085356A - 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 - Google Patents
3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법Info
- Publication number
- KR20260085356A KR20260085356A KR1020267016679A KR20267016679A KR20260085356A KR 20260085356 A KR20260085356 A KR 20260085356A KR 1020267016679 A KR1020267016679 A KR 1020267016679A KR 20267016679 A KR20267016679 A KR 20267016679A KR 20260085356 A KR20260085356 A KR 20260085356A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- salt
- present disclosure
- once daily
- nivolumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019035603 | 2019-02-28 | ||
| JPJP-P-2019-035603 | 2019-02-28 | ||
| JP2019112619 | 2019-06-18 | ||
| JPJP-P-2019-112619 | 2019-06-18 | ||
| PCT/JP2020/008527 WO2020175704A1 (ja) | 2019-02-28 | 2020-02-28 | 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法 |
| KR1020217030409A KR20210130774A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217030409A Division KR20210130774A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260085356A true KR20260085356A (ko) | 2026-06-09 |
Family
ID=72239799
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267016679A Pending KR20260085356A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 |
| KR1020267016683A Pending KR20260085357A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법 |
| KR1020217030410A Ceased KR20210131387A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법 |
| KR1020217030409A Ceased KR20210130774A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267016683A Pending KR20260085357A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법 |
| KR1020217030410A Ceased KR20210131387A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법 |
| KR1020217030409A Ceased KR20210130774A (ko) | 2019-02-28 | 2020-02-28 | 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220184082A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3932425A4 (cg-RX-API-DMAC7.html) |
| JP (7) | JPWO2020175704A1 (cg-RX-API-DMAC7.html) |
| KR (4) | KR20260085356A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2020229714B2 (cg-RX-API-DMAC7.html) |
| MA (2) | MA55088A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202045182A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020175697A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250007056A (ko) | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| US20220348662A1 (en) * | 2019-09-26 | 2022-11-03 | Janssen Pharmaceutica Nv | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
| WO2025046272A1 (en) | 2023-08-31 | 2025-03-06 | Taiho Pharmaceutical Co., Ltd. | Methods of treating cancer using futibatinib and pembrolizumab |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| WO2013108809A1 (ja) | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | 3,5-二置換ベンゼンアルキニル化合物及びその塩 |
| WO2016161239A1 (en) | 2015-04-03 | 2016-10-06 | Astex Therapeutics Limited | Fgfr/pd-1 combination therapy for the treatment of cancer |
| WO2017150725A1 (ja) | 2016-03-04 | 2017-09-08 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040004771A (ko) | 2002-07-05 | 2004-01-16 | 삼광유리공업주식회사 | 필름 코팅 유리컵 및 그 제조방법 |
| KR101480809B1 (ko) | 2012-03-26 | 2015-01-09 | 한국화학연구원 | 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말 |
| JP6084292B2 (ja) * | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
| KR20170066546A (ko) * | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| JP6572561B2 (ja) | 2015-03-03 | 2019-09-11 | ダイキン工業株式会社 | 熱交換器および空気調和機 |
| EA201890161A1 (ru) * | 2015-06-29 | 2018-06-29 | Верастэм, Инк. | Терапевтические композиции, комбинации и способы применения |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| SG10201913538VA (en) * | 2015-11-23 | 2020-02-27 | Five Prime Therapeutics Inc | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
| JP6409797B2 (ja) | 2016-02-24 | 2018-10-24 | 三菱電機株式会社 | 冷蔵庫 |
-
2020
- 2020-02-28 EP EP20763207.6A patent/EP3932425A4/en active Pending
- 2020-02-28 JP JP2021502667A patent/JPWO2020175704A1/ja active Pending
- 2020-02-28 WO PCT/JP2020/008509 patent/WO2020175697A1/ja not_active Ceased
- 2020-02-28 AU AU2020229714A patent/AU2020229714B2/en active Active
- 2020-02-28 KR KR1020267016679A patent/KR20260085356A/ko active Pending
- 2020-02-28 KR KR1020267016683A patent/KR20260085357A/ko active Pending
- 2020-02-28 JP JP2021502662A patent/JPWO2020175697A1/ja active Pending
- 2020-02-28 WO PCT/JP2020/008527 patent/WO2020175704A1/ja not_active Ceased
- 2020-02-28 MA MA055088A patent/MA55088A/fr unknown
- 2020-02-28 KR KR1020217030410A patent/KR20210131387A/ko not_active Ceased
- 2020-02-28 US US17/434,655 patent/US20220184082A1/en active Pending
- 2020-02-28 KR KR1020217030409A patent/KR20210130774A/ko not_active Ceased
- 2020-02-28 US US17/434,573 patent/US20220125793A1/en active Pending
- 2020-02-28 MA MA055091A patent/MA55091A/fr unknown
- 2020-02-28 EP EP20763687.9A patent/EP3932427A4/en active Pending
- 2020-02-28 AU AU2020228514A patent/AU2020228514B2/en active Active
- 2020-03-02 TW TW109106772A patent/TW202045182A/zh unknown
- 2020-03-02 TW TW109106773A patent/TW202039507A/zh unknown
-
2023
- 2023-05-19 JP JP2023083174A patent/JP2023096156A/ja active Pending
- 2023-06-22 JP JP2023102852A patent/JP2023112136A/ja active Pending
-
2024
- 2024-08-09 JP JP2024134396A patent/JP2024152860A/ja active Pending
-
2025
- 2025-02-18 JP JP2025024594A patent/JP2025075059A/ja active Pending
- 2025-05-26 AU AU2025203861A patent/AU2025203861A1/en active Pending
- 2025-05-26 AU AU2025203865A patent/AU2025203865A1/en active Pending
-
2026
- 2026-05-08 JP JP2026079170A patent/JP2026116557A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| WO2013108809A1 (ja) | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | 3,5-二置換ベンゼンアルキニル化合物及びその塩 |
| WO2016161239A1 (en) | 2015-04-03 | 2016-10-06 | Astex Therapeutics Limited | Fgfr/pd-1 combination therapy for the treatment of cancer |
| WO2017150725A1 (ja) | 2016-03-04 | 2017-09-08 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
Non-Patent Citations (14)
| Title |
|---|
| Cancer Res. 70, 2085-2094(2010) |
| Cell. 168:707-723(2017) |
| Cellular Physiology and Biochemistry, 33, p.633-645(2014) |
| frontirs in Immunology, 9, 2018, Article1310. doi:10. 3389/fimmu. 2018. 01310 |
| J. Clin. Oncol. 24, 3664-3671(2006) |
| JCO Precision Oncology(DOI:10. 1200/P0.18. 00117) July 24, 2018 |
| Mol. Cancer Res. 3, 655-667(2005) |
| N. Engl. J. Med., 366:2443-2454(2012) |
| N. Engl. J. Med., 375:819-829(2016) |
| Nat. Rev. Cancer 10:116-129(2010) |
| Nat. Rev. Cancer, 12:252-264(2012) |
| Oncotarget. 8:16052-16074(2017) |
| Sci. Transl. Med. 9, eaal3604(2017) |
| The Breast. 37, 126-133(2018) |
Also Published As
| Publication number | Publication date |
|---|---|
| MA55091A (fr) | 2022-01-05 |
| KR20210131387A (ko) | 2021-11-02 |
| EP3932427A1 (en) | 2022-01-05 |
| AU2020228514A1 (en) | 2021-10-07 |
| AU2025203861A1 (en) | 2025-06-19 |
| JP2026116557A (ja) | 2026-07-09 |
| JP2024152860A (ja) | 2024-10-25 |
| AU2020228514B2 (en) | 2025-02-27 |
| JPWO2020175704A1 (cg-RX-API-DMAC7.html) | 2020-09-03 |
| MA55088A (fr) | 2022-01-05 |
| JP2025075059A (ja) | 2025-05-14 |
| US20220184082A1 (en) | 2022-06-16 |
| JP2023112136A (ja) | 2023-08-10 |
| KR20260085357A (ko) | 2026-06-09 |
| AU2025203865A1 (en) | 2025-06-19 |
| US20220125793A1 (en) | 2022-04-28 |
| KR20210130774A (ko) | 2021-11-01 |
| JPWO2020175697A1 (cg-RX-API-DMAC7.html) | 2020-09-03 |
| TW202045182A (zh) | 2020-12-16 |
| TW202039507A (zh) | 2020-11-01 |
| AU2020229714B2 (en) | 2025-02-27 |
| WO2020175704A1 (ja) | 2020-09-03 |
| EP3932425A1 (en) | 2022-01-05 |
| WO2020175697A1 (ja) | 2020-09-03 |
| AU2020229714A1 (en) | 2021-10-07 |
| JP2023096156A (ja) | 2023-07-06 |
| EP3932425A4 (en) | 2022-12-07 |
| EP3932427A4 (en) | 2022-12-07 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |